

Aspira Pathlab & Diagnostics Limited

Regd. Office: Flat No. 2, R D Shah Building, Shraddhanand Road,

Opp. Railway Station, Ghatkopar (W), Mumbai 400 086

CIN: L85100MH1973PLC289209

Date: March 15,2024

To, **BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001.

Sub: Disclosure under Regulation 7(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 as amended ("SEBI Insider **Trading Regulations")- Continual Disclosure**

Dear Sir/Madam,

Please find enclosed herewith the following disclosure-

Form - C pursuant to Regulation 7(2) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 from Mr. Jay Arvind Bhanushali, Promoters Immediate Relative of the Company for the acquisition of Equity Shares from the market as on March 14, 2024 and March 15, 2024 respectively.

Thanking You, Yours Sincerely,

For Aspira Pathlab & Diagnostics Limited

Krupali Shah **Company Secretary & Compliance Officer**

Encl: as above

JAY ARVIND BHANUSHALI ADDRESS: C-34, KONARK INDRAPRASHTH, SARVODAYA NAGAR, VILLAGE NAHUR, MULUND (W), MUMBAI – 400080

Date: March 15, 2024

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001

Ref: ASPIRA PATHLAB & DIAGNOSTICS LIMITED

Sub: Regulation 7 (2) read with Regulation 6(2) – Continual disclosure of SEBI (Prohibition of Insider Trading) Regulations, 2015.

Dear Sir/Madam,

Please find enclosed herewith the Regulation 7(2) read with Regulation 6(2) – Continual disclosure of SEBI (Prohibition of Insider Trading) Regulations, 2015 as informed by me in Form C regarding acquisition of Equity Shares of the Company through market as on March 14, 2024 and March 15, 2024 respectively.

Please take it on your record.

Thanking You,

(Jay Arvind Bhanushali)

Encl: - as above

CC:-

ASPIRA PATHLAB & DIAGNOSTICS LIMITED Flat NO.2, R.D. Shah Bldg, Shraddhanand Road Opp. Ghatkopar Railway Station, Ghatkopar (West) Mumbai - 400086

FORM C

SEBI (Prohibition of Insider Trading) Regulations, 2015 [Regulation 7 (2) read with Regulation 6(2) - Continual Disclosure]

Name of the company: Aspira Pathlab & Diagnostics Limited

ISIN of the company: INE500C01017

Details of change in holding of Securities of Promoter, Member of the Promoter Group, Designated Person or Director of a listed companyand immediate relatives of

such persons and other such persons as mentioned in Regulation 6(2).

Name, PAN, CIN/DIN, & address with contact nos.	ofPerson	prior to acquisition/		Securities acquired /Disposed				Securities heldpost acquisition/ disposal		advice/ acquisition of shares/disposal of shares, specify			acquisition /disposal (on	exchange on which the trade was executed
		securiti es (For eg Shares Warrant	% of	Type of securit ies (For eg Shares , Warran ts, Conver tib le Debent ures, Rights entitle ment, etc.)	No.	Value	se/sale Pledge / Revocat ion /	securities	shareh	From	То		public/ rights/ preferential offer/ off market/ Inter-se transfer, ESOPs, etc.)	
Jay Arvind Bhanushali	Immediate	Equity	1,79,605	Equity	6,309	2,01,888	Purchase	Equity	1,86,942	14-03-2024	14-03-2024	14-03-2024	Market	BSE
PAN: DROPB8272B Address: C-34, Konark	Relative of Promoter	Shares	(1.75%)	Shares	1,028	32,896		Shares	(1.82%)	15-03-2024	15-03-2024	15-03-2024	Purchase	
Indraprashth, Sarvodaya Nagar, Village Nahur, Mulund (W), Mumbai – 400080	riomoter			Total	7,337	2,34,784								

Note: (i) "Securities" shall have the meaning as defined under regulation 2(1)(i) of SEBI (Prohibition of Insider Trading) Regulations, 2015.

(ii) Value of transaction excludes taxes/brokerage/any other charges

(Jay Arvind Bhanushali)

Date: 15-03-2024 Place: Mumbai